Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2017

26.04.2017 | Original Article

Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer

verfasst von: Sang-Won Kim, O Kyu Noh, Ji Hun Kim, Mison Chun, Young-Taek Oh, Seok Yun Kang, Hyun Woo Lee, Rae Woong Park, Dukyong Yoon

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to present the clinical outcomes of adjuvant concurrent chemoradiotherapy (CCRT) with low-dose daily cisplatin regimen compared to the conventional 5-fluorouracil (5-FU)-based regimen for extrahepatic bile duct cancer (EHBDC).

Methods

From October 1994 to April 2013, 41 patients received adjuvant CCRT with low-dose daily regimen or 5-FU-based regimens. Nineteen patients received low-dose of cisplatin just before every delivery of radiation therapy, and 21 patients received two cycles of 5-FU-based regimen during radiotherapy. We compared the clinical outcomes between two adjuvant CCRT regimens.

Results

Adjuvant CCRT with low-dose daily cisplatin showed comparable toxicity profiles compared with that of a 5-FU-based regimen. The median follow-up time was 33 months (range, 5–205), and the 5-year overall survival (OS), locoregional recurrence-free survival (LRRFS), and distant metastasis-free survival (DMFS) were 34.2, 50.8, and 49.7%, respectively. Univariable analyses showed no significant differences in OS, LRRFS, and DMFS between the groups with two regimens. In multivariable analyses, chemotherapeutic regimen was a significant prognostic factor for OS, favoring the low-dose daily cisplatin regimen (HR = 2.491, p = 0.036) over 5-FU-based regimen, though not for LRRFS (p = 0.642) and DMFS (p = 0.756).

Conclusions

Adjuvant CCRT with low-dose daily cisplatin regimen showed acceptable toxicities and survivals compared to those of the 5-FU-based regimen. Low-dose daily cisplatin can be one of the feasible regimens for adjuvant CCRT for EHBDC.
Literatur
2.
Zurück zum Zitat Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M, DeMatteo RP, Wagman R, Blumgart LH, Fong Y (2003) Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98(8):1689–1700. doi:10.1002/cncr.11699 CrossRefPubMed Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M, DeMatteo RP, Wagman R, Blumgart LH, Fong Y (2003) Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98(8):1689–1700. doi:10.​1002/​cncr.​11699 CrossRefPubMed
5.
Zurück zum Zitat Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, Evans D, Abdalla EK, Thomas MB, Das P, Wistuba II, Krishnan S, Vauthey JN (2008) Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 15(11):3147–3156. doi:10.1245/s10434-008-9998-7 CrossRefPubMed Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, Evans D, Abdalla EK, Thomas MB, Das P, Wistuba II, Krishnan S, Vauthey JN (2008) Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 15(11):3147–3156. doi:10.​1245/​s10434-008-9998-7 CrossRefPubMed
6.
Zurück zum Zitat Nelson JW, Ghafoori AP, Willett CG, Tyler DS, Pappas TN, Clary BM, Hurwitz HI, Bendell JC, Morse MA, Clough RW, Czito BG (2009) Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 73(1):148–153. doi:10.1016/j.ijrobp.2008.07.008 CrossRefPubMed Nelson JW, Ghafoori AP, Willett CG, Tyler DS, Pappas TN, Clary BM, Hurwitz HI, Bendell JC, Morse MA, Clough RW, Czito BG (2009) Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 73(1):148–153. doi:10.​1016/​j.​ijrobp.​2008.​07.​008 CrossRefPubMed
7.
Zurück zum Zitat Kim TH, Han SS, Park SJ, Lee WJ, Woo SM, Moon SH, Yoo T, Kim SS, Kim SH, Hong EK, Kim DY, Park JW (2011) Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys 81(5):e853–e859. doi:10.1016/j.ijrobp.2010.12.019 CrossRefPubMed Kim TH, Han SS, Park SJ, Lee WJ, Woo SM, Moon SH, Yoo T, Kim SS, Kim SH, Hong EK, Kim DY, Park JW (2011) Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys 81(5):e853–e859. doi:10.​1016/​j.​ijrobp.​2010.​12.​019 CrossRefPubMed
8.
Zurück zum Zitat Park JH, Choi EK, Ahn SD, Lee SW, Song SY, Yoon SM, Kim YS, Lee YS, Lee SG, Hwang S, Lee YJ, Park KM, Kim TW, Chang HM, Lee JL, Kim JH (2011) Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 79(3):696–704. doi:10.1016/j.ijrobp.2009.12.031 CrossRefPubMed Park JH, Choi EK, Ahn SD, Lee SW, Song SY, Yoon SM, Kim YS, Lee YS, Lee SG, Hwang S, Lee YJ, Park KM, Kim TW, Chang HM, Lee JL, Kim JH (2011) Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 79(3):696–704. doi:10.​1016/​j.​ijrobp.​2009.​12.​031 CrossRefPubMed
9.
Zurück zum Zitat Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW (2012) Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience. Am J Clin Oncol 35(2):136–140. doi:10.1097/COC.0b013e318209aa29 CrossRefPubMed Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW (2012) Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience. Am J Clin Oncol 35(2):136–140. doi:10.​1097/​COC.​0b013e318209aa29​ CrossRefPubMed
11.
Zurück zum Zitat Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L (2000) Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18(7):1458–1464CrossRefPubMed Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L (2000) Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18(7):1458–1464CrossRefPubMed
12.
Zurück zum Zitat Uitterhoeve AL, Belderbos JS, Koolen MG, van der Vaart PJ, Rodrigus PT, Benraadt J, Koning CC, Gonzalez DG, Bartelink H (2000) Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. Eur J Cancer 36(5):592–600. doi:10.1016/S0959-8049(99)00315-9 CrossRefPubMed Uitterhoeve AL, Belderbos JS, Koolen MG, van der Vaart PJ, Rodrigus PT, Benraadt J, Koning CC, Gonzalez DG, Bartelink H (2000) Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. Eur J Cancer 36(5):592–600. doi:10.​1016/​S0959-8049(99)00315-9 CrossRefPubMed
13.
Zurück zum Zitat Kawakami H, Uno T, Isobe K, Ueno N, Aruga T, Sudo K, Yamaguchi T, Saisho H, Kawata T, Ito H (2005) Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 62(5):1357–1362. doi:10.1016/j.ijrobp.2004.12.041 CrossRefPubMed Kawakami H, Uno T, Isobe K, Ueno N, Aruga T, Sudo K, Yamaguchi T, Saisho H, Kawata T, Ito H (2005) Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 62(5):1357–1362. doi:10.​1016/​j.​ijrobp.​2004.​12.​041 CrossRefPubMed
15.
16.
Zurück zum Zitat Im JH, Seong J, Lee IJ, Park JS, Yoon DS, Kim KS, Lee WJ, Park KR (2016) Surgery alone versus surgery followed by chemotherapy and radiotherapy in resected extrahepatic bile duct cancer: treatment outcome analysis of 336 patients. Cancer Res Treat 48(2):583–595. doi:10.4143/crt.2015.091 CrossRefPubMed Im JH, Seong J, Lee IJ, Park JS, Yoon DS, Kim KS, Lee WJ, Park KR (2016) Surgery alone versus surgery followed by chemotherapy and radiotherapy in resected extrahepatic bile duct cancer: treatment outcome analysis of 336 patients. Cancer Res Treat 48(2):583–595. doi:10.​4143/​crt.​2015.​091 CrossRefPubMed
17.
Zurück zum Zitat Hoehn RS, Wima K, Ertel AE, Meier A, Ahmad SA, Shah SA, Abbott DE (2015) Adjuvant chemotherapy and radiation therapy is associated with improved survival for patients with extrahepatic cholangiocarcinoma. Ann Surg Oncol 22(Suppl 3):S1133–S1139. doi:10.1245/s10434-015-4599-8 CrossRefPubMed Hoehn RS, Wima K, Ertel AE, Meier A, Ahmad SA, Shah SA, Abbott DE (2015) Adjuvant chemotherapy and radiation therapy is associated with improved survival for patients with extrahepatic cholangiocarcinoma. Ann Surg Oncol 22(Suppl 3):S1133–S1139. doi:10.​1245/​s10434-015-4599-8 CrossRefPubMed
18.
Zurück zum Zitat Hanawa S, Mitsuhashi A, Usui H, Yamamoto N, Watanabe-Nemoto M, Nishikimi K, Uehara T, Tate S, Uno T, Shozu M (2015) Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older. Int J Gynecol Cancer 25(5):891–896. doi:10.1097/IGC.0000000000000436 CrossRefPubMed Hanawa S, Mitsuhashi A, Usui H, Yamamoto N, Watanabe-Nemoto M, Nishikimi K, Uehara T, Tate S, Uno T, Shozu M (2015) Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older. Int J Gynecol Cancer 25(5):891–896. doi:10.​1097/​IGC.​0000000000000436​ CrossRefPubMed
19.
Zurück zum Zitat Lim KH, Oh DY, Chie EK, Jang JY, Im SA, Kim TY, Kim SW, Ha SW, Bang YJ (2009) Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. BMC Cancer 9:345. doi:10.1186/1471-2407-9-345 CrossRefPubMedPubMedCentral Lim KH, Oh DY, Chie EK, Jang JY, Im SA, Kim TY, Kim SW, Ha SW, Bang YJ (2009) Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. BMC Cancer 9:345. doi:10.​1186/​1471-2407-9-345 CrossRefPubMedPubMedCentral
Metadaten
Titel
Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer
verfasst von
Sang-Won Kim
O Kyu Noh
Ji Hun Kim
Mison Chun
Young-Taek Oh
Seok Yun Kang
Hyun Woo Lee
Rae Woong Park
Dukyong Yoon
Publikationsdatum
26.04.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2017
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-017-3312-y

Weitere Artikel der Ausgabe 6/2017

Cancer Chemotherapy and Pharmacology 6/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.